A study showed that FOXD3 could activate osteopontin enhancer that is expressed in totipotent embryonic stem cells, which suggests that FOXD3 is a key transcriptional factor involved in managing the developmental aspect of the complex pathogenesis of BA (Guo et al., 2002, 3). This evidence concerns the gene SPP1 and breast angiosarcoma.